文献速递遗传性与小管间质肾病慢性肾脏病

原发性高草酸尿症2型患者并发症显著且需密切随访

Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up.
PubMed 文献 · Kidney Int · 2019-09-03

该研究基于OxalEurope登记库中101例基因确诊的原发性高草酸尿症2型患者进行回顾性分析,中位随访12.4年。结果显示患者慢性肾脏病2期及以上常见,中位肾脏生存43.3年,基因型、生化指标与肾脏结局无关,需24小时尿分析和基因检测准确诊断并密切随访。

要点

  • 原发性高草酸尿症2型患者慢性肾脏病发生率高,中位肾脏生存43.3年。
  • 尿路结石是最常见首发表现,占82.8%。
  • 需通过24小时尿分析和基因检测确诊并密切随访。

核心结论

  • 原发性高草酸尿症2型并发症显著,需通过24小时尿分析和基因检测准确诊断并密切随访。

研究设计与样本

  • 回顾性记录审查OxalEurope登记库中11个国家101例基因确诊的原发性高草酸尿症2型患者,中位随访12.4年。

主要发现

  • 尿路结石是最常见首发特征,占82.8%的患者。
  • 238次点尿分析中23次(9.7%)草酸盐在正常范围,而24小时尿液收集低于4%。
  • 24小时草酸盐排泄的个体内变异中位数为34.1%。
  • 89例可随访患者中45例发生慢性肾脏病2期或以上,22例达到5期。
  • 中位肾脏生存43.3年,11例患者接受15次肾移植(1例联合肝移植)。

关键数值与推荐

  • 索引病例首次症状和诊断的中位年龄分别为3.2岁和8.0岁。
  • 基因分析发现GRHPR基因18个新突变。
  • 肾脏结局与基因型、生化参数或初始存在的肾钙质沉着无关。

临床怎么用

  • 对疑似患者应采用24小时尿分析而非点尿进行草酸盐评估。
  • 基因检测有助于确诊原发性高草酸尿症2型。
  • 确诊患者需长期密切随访肾功能。

局限性

  • 回顾性研究设计。
  • 12例患者失访。
  • 早期报告受限于患者数量少和随访期短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary hyperoxaluria type 2 is a rare inherited disorder of glyoxylate metabolism causing nephrocalcinosis, renal stone formation and ultimately kidney failure. Previously, primary hyperoxaluria type 2 was considered to have a more favorable prognosis than primary hyperoxaluria type 1, but earlier reports are limited by low patient numbers and short follow up periods. Here we report on the clinical, genetic, and biochemical findings from the largest cohort of patients with primary hyperoxaluria type 2, obtained by a retrospective record review of genetically confirmed cases in the OxalEurope registry, a dataset containing 101 patients from eleven countries. Median follow up was 12.4 years. Median ages at first symptom and diagnosis for index cases were 3.2 years and 8.0 years, respectively. Urolithiasis was the most common presenting feature (82.8% of patients). Genetic analysis revealed 18 novel mutations in the GRHPR gene. Of 238 spot-urine analyses, 23 (9.7%) were within the normal range for oxalate as compared to less than 4% of 24-hour urine collections. Median intra-individual variation of 24-hour oxalate excretion was substantial (34.1%). At time of review, 12 patients were lost to follow-up; 45 of the remaining 89 patients experienced chronic kidney disease stage 2 or greater and 22 patients had reached stage 5. Median renal survival was 43.3 years, including 15 kidney transplantations in 11 patients (1 combined with liver transplantation). Renal outcome did not correlate with genotype, biochemical parameters or initially present nephrocalcinosis. Thus, primary hyperoxaluria type 2 is a disease with significant morbidity. Accurate diagnosis by 24-hour urine analysis and genetic testing are required with careful follow-up.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Garrelfs SF, Rumsby G, Peters-Sengers H, et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int. 2019. PMID: 31685312. doi:10.1016/j.kint.2019.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。